Crossmark

TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s13046-020-01713-9

Published Online: 2020-10-15

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ruicci, Kara M.

Meens, Jalna

Plantinga, Paul

Stecho, William

Pinto, Nicole

Yoo, John

Fung, Kevin

MacNeil, Danielle

Mymryk, Joe S.

Barrett, John W.

Howlett, Christopher J.

Boutros, Paul C.

Ailles, Laurie

Nichols, Anthony C.
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research (340674)
License Information

Text and Data Mining valid from 2020-10-15

Version of Record valid from 2020-10-15
More Information

Article History

Received: 16 January 2020

Accepted: 16 September 2020

First Online: 15 October 2020

Ethics approval and consent to participate

: Mice were handled in accordance with the AUP 1542 approved by the University Health Network Animal Care Committee and in accordance with the CCAC regulations.

: Not applicable.

: ACN has received clinical trial funding from Novartis for a Window of Opportunity Trial using alpelisib in HNSCC patients (NCT03138070).

Document is current

Any future updates will be listed below